ID   RH9/CB
AC   CVCL_U265
DR   cancercelllines; CVCL_U265
DR   IZSLER; BS TCL 164
DR   Wikidata; Q54950373
RX   Patent=US5580772;
CC   Group: Patented cell line.
CC   Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11622.
CC   Population: Caucasian.
CC   Characteristics: Established from parent cell line by co-cultivation with peripheral blood mononuclear cells isolated from a patient with idiopathic CD4 + T lymphocitopenia (ICL). Contains human intracisternal A-type particles type II (HIAP-II) (IZSLER=BS TCL 164).
CC   Sequence variation: Mutation; HGNC; HGNC:7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
CC   Cell type: T-cell; CL=CL_0000084.
DI   NCIt; C3366; Sezary syndrome
DI   ORDO; Orphanet_3162; Sezary syndrome
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_U264 ! RH9
SX   Male
AG   53Y
CA   Cancer cell line
DT   Created: 03-02-14; Last updated: 19-12-24; Version: 16
//
RX   Patent=US5580772;
RA   Garry, Robert F. Jr.
RT   "Association between a novel human intracisternal A-type retroviral
RT   particle-type II (HIAP-II) and idiopathic CD4+ T-lymphocytopenia
RT   (ICL).";
RL   Patent number US5580772, 03-Dec-1996.
//